Calcium channel blockers for lung function improvement in asthma

Chiu, Kam Yu; Li, Jian Guo

doi:10.1016/j.anai.2017.08.013

Cited by 18 publications

(13 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 23 − 25 Recently, the same CCBs tested here were shown to have a beneficial effect on the lung function of asthma patients, providing evidence that CCBs act in the lungs. 26 More evidence that interference with the cellular Ca 2+ balance suppresses viral growth comes from nebulizers used for asthma medications. Nebulizers are supplemented with EDTA as a preservative, which may help to deplete extracellular Ca 2+ 27 and may provide a clue as to why asthma (despite being a respiratory illness) is not on the top ten list of chronic health problems of people who died of COVID-19.…”

mentioning

confidence: 99%

Inhibitors of L-Type Calcium Channels Show Therapeutic Potential for Treating SARS-CoV-2 Infections by Preventing Virus Entry and Spread

et al. 2021

View full text Add to dashboard Cite

COVID-19 is caused by a novel coronavirus, the severe acute respiratory syndrome coronavirus (CoV)-2 (SARS-CoV-2). The virus is responsible for an ongoing pandemic and concomitant public health crisis around the world. While vaccine development is proving to be highly successful, parallel drug development approaches are also critical in the response to SARS-CoV-2 and other emerging viruses. Coronaviruses require Ca 2+ ions for host cell entry, and we have previously shown that Ca 2+ modulates the interaction of the viral fusion peptide with host cell membranes. In an attempt to accelerate drug repurposing, we tested a panel of L-type calcium channel blocker (CCB) drugs currently developed for other conditions to determine whether they would inhibit SARS-CoV-2 infection in cell culture. All the CCBs tested showed varying degrees of inhibition, with felodipine and nifedipine strongly limiting SARS-CoV-2 entry and infection in epithelial lung cells at concentrations where cell toxicity was minimal. Further studies with pseudotyped particles displaying the SARS-CoV-2 spike protein suggested that inhibition occurs at the level of virus entry. Overall, our data suggest that certain CCBs have the potential to treat SARS-CoV-2 infections and are worthy of further examination for possible treatment of COVID-19.

show abstract

mentioning

confidence: 99%

Inhibitors of L-Type Calcium Channels Show Therapeutic Potential for Treating SARS-CoV-2 Infections by Preventing Virus Entry and Spread

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In this context, it is noteworthy that CCBs are believed to not only affect cardiovascular muscles but also airway smooth muscle cells, which rely on Ltype calcium channels for their contraction [24][25][26] . A recent study using the CCBs tested here for their potential to improve lung function in asthma patients and concluded there was a beneficial effect, providing evidence that CCBs act in the lungs 27 . This also links to the observation that asthma is not on the top ten list of chronic health problems that people suffered from who died of Covid-19 as one would expect this respiratory condition to be.…”

mentioning

confidence: 58%

Inhibitors of L-type calcium channels show therapeutic potential for treating SARS-CoV-2 infections by preventing virus entry and spread

Straus

Bidon

Tang

et al. 2020

Preprint

View full text Add to dashboard Cite

Covid-19 has infected more than 14 million people worldwide causing over 600.000 deaths1. The disease is caused by the severe acute respiratory syndrome coronavirus (CoV) 2 (SARS-CoV-2), which shares a high sequence similarity to SARS CoV2. Currently there are no vaccinations available to provide protection and the only antiviral therapy in active use in patients is remdesivir, which currently provides only limited benefit3. Hence, there is an urgent need for antiviral therapies against SARS CoV 2. SARS CoV requires Ca2+ ions for host cell entry4 and based on the similarity between SARS CoV and SARS CoV 25 it is highly likely that the same requirements exist for the two viruses. Here, we tested whether FDA-approved calcium channel blocker (CCB) drugs are efficacious to inhibit the spread of SARS CoV 2 in cell culture. Our data shows that amlodipine, felodipine and nifedipine limit the growth of SARS CoV 2 in epithelial kidney (Vero E6) and epithelial lung (Calu-3) cells. We observed some differences in the inhibition efficacy of the drugs in the two different cell lines, but with felodopine and nifedipine having the greatest effect. Overall, our data suggest that CCBs have a high potential to treat SARS CoV 2 infections and their current FDA approval would allow for a fast repurposing of these drugs.

show abstract

“…• Пациентам с АГ в сочетании с БА и/или хронической обструктивной болезнью легких (ХОБЛ) с целью достижения целевого уровня АД в качестве стартовой АГТ не рекомедовано назначение ББ, рекомендуется назначение блокаторов РААС и АК [206][207][208][209][210][211] [212].…”

Section: артериальная гипертензия у пациентов с заболеваниями легкихunclassified

Arterial hypertension in adults. Clinical guidelines 2020

et al. 2020

View full text Add to dashboard Cite

show abstract

Calcium channel blockers for lung function improvement in asthma

Cited by 18 publications

References 51 publications

Inhibitors of L-Type Calcium Channels Show Therapeutic Potential for Treating SARS-CoV-2 Infections by Preventing Virus Entry and Spread

Inhibitors of L-Type Calcium Channels Show Therapeutic Potential for Treating SARS-CoV-2 Infections by Preventing Virus Entry and Spread

Inhibitors of L-type calcium channels show therapeutic potential for treating SARS-CoV-2 infections by preventing virus entry and spread

Arterial hypertension in adults. Clinical guidelines 2020

Contact Info

Product

Resources

About